Article Information
History
- August 30, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Zahi I. Mitri1,2,†,
- Allison L. Creason3,4,†,
- Jayne M. Stommel3,†,
- Daniel Bottomly3,
- Tugba Y. Ozmen3,6,
- Matthew J. Rames3,6,
- Furkan Ozmen3,6,
- Boyoung Jeong3,6,
- Natalia Lukashchuk7,
- Jack Ashton7,
- Jeong Youn Lim5,
- Shamilene Sivagnanam6,
- Konjit Betra6,
- Jinho Lee3,8,
- Marilyne Labrie9,10,11,
- SMMART Clinical Trials Program3,
- Lisa M. Coussens3,6,
- Christopher L. Corless3,8,
- Shannon K. McWeeney3,12 and
- Gordon B. Mills3,6,*
- 1British Columbia Cancer Agency, Vancouver, BC, Canada
- 2Division of Medical Oncology, University of British Columbia, Vancouver, BC, Canada
- 3Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA
- 4Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA
- 5Biostatistics Shared Resource, Oregon Health & Science University, Portland, OR, USA
- 6Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR, USA
- 7Translational Medicine, Oncology Research and Development (R&D), AstraZeneca, Cambridge, United Kingdom
- 8Knight Diagnostic Laboratories, Oregon Health & Science University, Portland, OR, USA
- 9Department of Immunology and Cell Biology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Canada
- 10Centre de Recherche du Centre Hospitalier de l’Université de Sherbrooke (CRCHUS), Sherbrooke, Canada
- 11Institut de Recherche sur le Cancer de l’Université de Sherbrooke (IRCUS), Sherbrooke, Canada
- 12Division of Bioinformatics and Computational Biology, Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, OR, USA
- ↵*Corresponding Author millsg{at}ohsu.edu
↵† These authors contributed equally to this work.
Posted August 30, 2024.
Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab: Multi-omic Analysis of Serial Biopsies in the AMTEC Trial
